Veritas In Silico Inc. 130AShort Interest
No institution currently reports a short position of 0.5% or more in Veritas In Silico Inc. (130A). The last disclosure was on 2026-11-09 (Morgan Stanley MUFG Securities Co., Ltd., 0.33%).
Estimated short interest
0.00%
±0.00%
Estimated position (shares)
0
As of 2026-11-18
Holders (0.5% or more)
0 firms
295 reports
Estimated short interest is the sum of positions of 0.5% or more reported within the past year. It also excludes 7 institutions that fell below 0.5%. How estimates are calculated
Disclosure History Summary
| First disclosure | 2024-02-15 |
|---|---|
| Latest disclosure | 2026-11-09 (Morgan Stanley MUFG Securities Co., Ltd., 0.33%) |
| Reporting institutions | 7 firms (295 reports) |
| Peak estimated short interest | 4.56% (2024-08-01, 2 holders) |
Short Interest Trend Last 5 years, by institution, % of shares outstanding
Estimated short interest stacked by institution, counting only positions of 0.5% or more reported within the past year. The 5 largest current holders are colored and the rest are grouped as "Others". Hover over (or tap) a bar to see the breakdown.
- Integrated Core Strategies (Asia) Pte. Ltd.
- Morgan Stanley MUFG Securities Co., Ltd.
- UBS AG
- Barclays Capital Securities Ltd
- MERRILL LYNCH INTERNATIONAL
- Others
0.00%
Estimated short interest, 2026-11-18
Current Positions by Short Seller Latest report of each holder
| Last report | Short seller | Position (shares) | Ratio | Change | Status |
|---|---|---|---|---|---|
| 2026-01-28 | UBS AG | Position 30,500 shares | Ratio 0.47% | ▼0.03% | Below 0.5% |
| 2026-04-15 | MERRILL LYNCH INTERNATIONAL | Position 29,100 shares | Ratio 0.44% | ▼0.07% | Below 0.5% |
| 2026-06-19 | Barclays Capital Securities Ltd | Position 27,300 shares | Ratio 0.42% | ▼0.17% | Below 0.5% |
| 2024-10-22 | Integrated Core Strategies (Asia) Pte. Ltd. | Position 25,600 shares | Ratio 0.39% | ▼0.18% | Below 0.5% |
| 2025-08-05 | Nomura International plc | Position 23,800 shares | Ratio 0.36% | ▼0.35% | Below 0.5% |
| 2026-11-09 | Morgan Stanley MUFG Securities Co., Ltd. | Position 21,600 shares | Ratio 0.33% | ▼0.26% | Below 0.5% |
| 2026-10-29 | GOLDMAN SACHS INTERNATIONAL | Position 19,800 shares | Ratio 0.30% | ▼0.21% | Below 0.5% |
Disclosure History 295 in total
| Trade date | Short seller | Position (shares) | Ratio | Change | Note |
|---|---|---|---|---|---|
| 2026-11-09 | Morgan Stanley MUFG Securities Co., Ltd. | Position 21,600 shares | Ratio 0.33% | ▼0.26% | Below 0.5% |
| 2026-10-30 | Morgan Stanley MUFG Securities Co., Ltd. | Position 38,300 shares | Ratio 0.59% | ▼0.17% | — |
| 2026-10-29 | GOLDMAN SACHS INTERNATIONAL | Position 19,800 shares | Ratio 0.30% | ▼0.21% | Below 0.5% |
| 2026-10-29 | Morgan Stanley MUFG Securities Co., Ltd. | Position 49,800 shares | Ratio 0.76% | ▼0.20% | — |
| 2026-10-26 | Morgan Stanley MUFG Securities Co., Ltd. | Position 62,700 shares | Ratio 0.96% | ▲0.12% | — |
| 2026-10-22 | GOLDMAN SACHS INTERNATIONAL | Position 33,600 shares | Ratio 0.51% | ▲0.06% | — |
| 2026-10-22 | Morgan Stanley MUFG Securities Co., Ltd. | Position 54,600 shares | Ratio 0.84% | ▲0.20% | — |
| 2026-10-21 | Morgan Stanley MUFG Securities Co., Ltd. | Position 41,600 shares | Ratio 0.64% | ▲0.35% | — |
| 2026-07-29 | Morgan Stanley MUFG Securities Co., Ltd. | Position 28,300 shares | Ratio 0.43% | ▼0.08% | Below 0.5% |
| 2026-06-19 | Barclays Capital Securities Ltd | Position 27,300 shares | Ratio 0.42% | ▼0.17% | Below 0.5% |
| 2026-06-15 | Morgan Stanley MUFG Securities Co., Ltd. | Position 33,300 shares | Ratio 0.51% | ▲0.11% | — |
| 2026-06-11 | Barclays Capital Securities Ltd | Position 38,900 shares | Ratio 0.59% | ▼0.10% | — |
| 2026-06-04 | Barclays Capital Securities Ltd | Position 45,300 shares | Ratio 0.69% | ▲0.09% | — |
| 2026-06-03 | Barclays Capital Securities Ltd | Position 45,700 shares | Ratio 0.70% | ▲0.10% | — |
| 2026-05-29 | Barclays Capital Securities Ltd | Position 39,400 shares | Ratio 0.60% | ▲0.07% | — |
| 2026-05-22 | Morgan Stanley MUFG Securities Co., Ltd. | Position 31,100 shares | Ratio 0.47% | ▼0.12% | Below 0.5% |
| 2026-05-20 | Morgan Stanley MUFG Securities Co., Ltd. | Position 38,800 shares | Ratio 0.59% | ▼0.08% | — |
| 2026-05-19 | Morgan Stanley MUFG Securities Co., Ltd. | Position 43,500 shares | Ratio 0.67% | ▼0.12% | — |
| 2026-05-14 | Barclays Capital Securities Ltd | Position 34,800 shares | Ratio 0.53% | ▲0.07% | — |
| 2026-05-01 | Barclays Capital Securities Ltd | Position 30,200 shares | Ratio 0.46% | ▼0.07% | Below 0.5% |
| 2026-04-30 | Barclays Capital Securities Ltd | Position 35,000 shares | Ratio 0.53% | ▲0.04% | — |
| 2026-04-28 | Barclays Capital Securities Ltd | Position 32,400 shares | Ratio 0.49% | ▼0.12% | Below 0.5% |
| 2026-04-21 | Barclays Capital Securities Ltd | Position 39,600 shares | Ratio 0.61% | ▲0.07% | — |
| 2026-04-16 | Barclays Capital Securities Ltd | Position 35,200 shares | Ratio 0.54% | ▲0.05% | — |
| 2026-04-15 | MERRILL LYNCH INTERNATIONAL | Position 29,100 shares | Ratio 0.44% | ▼0.07% | Below 0.5% |
| 2026-04-15 | Barclays Capital Securities Ltd | Position 32,200 shares | Ratio 0.49% | ▼0.05% | Below 0.5% |
| 2026-04-14 | MERRILL LYNCH INTERNATIONAL | Position 33,100 shares | Ratio 0.51% | ▼0.12% | — |
| 2026-04-13 | MERRILL LYNCH INTERNATIONAL | Position 41,100 shares | Ratio 0.63% | ▼0.16% | — |
| 2026-04-13 | Barclays Capital Securities Ltd | Position 35,400 shares | Ratio 0.54% | ▲0.13% | — |
| 2026-04-10 | MERRILL LYNCH INTERNATIONAL | Position 51,600 shares | Ratio 0.79% | ▼0.09% | — |
Shorted Stocks in the Same Industry Pharmaceutical
| Stock | Estimated ratio | Short sellers |
|---|---|---|
| GNI Group Ltd.2160 | 11.16% | 7 firms |
| Oncolys BioPharma Inc.4588 | 10.35% | 7 firms |
| HEALIOS K.K.4593 | 10.20% | 5 firms |
| SymBio Pharmaceuticals Limited4582 | 9.46% | 7 firms |
| Nxera Pharma Co.,Ltd.4565 | 7.35% | 5 firms |
Related Stocks Same TSE 33 sector
| Stock | Market | TSE 33 Sector | TOPIX-17 Sector | Index |
|---|---|---|---|---|
| Chordia Therapeutics Inc.190A | Growth Market(Domestic) | Pharmaceutical | Pharmaceutical | |
| TAUNS Laboratories,Inc.197A | Standard Market(Domestic) | Pharmaceutical | Pharmaceutical | |
| PRISM BioLab Co.,LTD206A | Growth Market(Domestic) | Pharmaceutical | Pharmaceutical | |
| GNI Group Ltd.2160 | Growth Market(Domestic) | Pharmaceutical | Pharmaceutical | |
| Heartseed Inc.219A | Growth Market(Domestic) | Pharmaceutical | Pharmaceutical | |
| Noile-Immune Biotech Inc.4893 | Growth Market(Domestic) | Pharmaceutical | Pharmaceutical | |
| Cuorips Inc.4894 | Growth Market(Domestic) | Pharmaceutical | Pharmaceutical | |
| K Pharma,Inc.4896 | Growth Market(Domestic) | Pharmaceutical | Pharmaceutical | |
| Innovacell Inc.504A | Growth Market(Domestic) | Pharmaceutical | Pharmaceutical | |
| J-Pharma Co.,Ltd.520A | Growth Market(Domestic) | Pharmaceutical | Pharmaceutical |